Combined ileal biomarkers can discriminate responders from non-responders to vedolizumab therapy in Crohn's disease

(1) University of Pennsylvania,Philadelphia,United States

(2) University of Arkansas for Medical Sciences,Little Rock,United States

(3) Cleveland Clinic Foundation, Cleavland,Clevland,United States

(4) Washington University School Of Medicine, St Louis, Mo,St. Louis,United States

(5) Washington University School of Medicine,St. Louis,United States

(6) University of Florida,Gainesville,United States

(7) Baylor College of Medicine,Houston,United States

(8) Brigham and Womens Hospital,Little Rock,United States

(9) Cleveland Clinic Foundation Digestive Disease Institute,Cleveland,United States

This item was part of the Late breaking abstracts: IBD Highlights session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019